Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux

References

• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:3584-90; PMID:19487381; http://dx.doi.org/10.1200/JCO.2008.20.1293
   PubMed Web of Science ®Google Scholar
• Grepin R, Ambrosetti D, Marsaud A, Gastaud L, Amiel J, Pedeutour F, Pages G. The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma. PLoS ONE 2014; 9:e89449; PMID:24676409; http://dx.doi.org/10.1371/journal.pone.0089449
   PubMed Web of Science ®Google Scholar
• Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 2009; 69:2506-13; PMID:19244102; http://dx.doi.org/10.1158/0008-5472.CAN-08-4323
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010; 13:1-14; PMID:20012482; http://dx.doi.org/10.1007/s10456-009-9160-6
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010; 28:2144-50; PMID:20368553; http://dx.doi.org/10.1200/JCO.2009.26.7849
   PubMed Web of Science ®Google Scholar
• Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V, Nabissi M, Bonfili L, Eleuteri AM, Mozzicafreddo M, Burattini L, et al. Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer 2013; 109:1040-50; PMID:23887605; http://dx.doi.org/10.1038/bjc.2013.420
   PubMed Web of Science ®Google Scholar
• Abdel-Aziz AK, Shouman S, El-Demerdash E, Elgendy M, Abdel-Naim AB. Chloroquine synergizes sunitinib cytotoxicity via modulating autophagic, apoptotic and angiogenic machineries. Chem Biol Interact 2014; 217:28-40; PMID:24751611; http://dx.doi.org/10.1016/j.cbi.2014.04.007
   PubMed Web of Science ®Google Scholar
• Ikeda T, Ishii KA, Saito Y, Miura M, Otagiri A, Kawakami Y, Shimano H, Hara H, Takekoshi K. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells. J Pharmacol Sci 2013; 121:67-73; PMID:23269235; http://dx.doi.org/10.1254/jphs.12158FP
   PubMed Web of Science ®Google Scholar
• Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, et al. Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance. Clin Cancer Res 2011; 17:7337-46; PMID:21980135; http://dx.doi.org/10.1158/1078-0432.CCR-11-1667
   PubMed Web of Science ®Google Scholar
• Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res 2010; 70:1053-62; PMID:20103629; http://dx.doi.org/10.1158/0008-5472.CAN-09-3722
   PubMed Web of Science ®Google Scholar
• Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J Pharm Sci 2007; 96:729-46; PMID:17117426; http://dx.doi.org/10.1002/jps.20792
   PubMed Web of Science ®Google Scholar
• Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
   PubMed Web of Science ®Google Scholar
• Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-75; PMID:18305538; http://dx.doi.org/10.1038/nature06639
   PubMed Web of Science ®Google Scholar
• Stanton MJ, Dutta S, Zhang H, Polavaram NS, Leontovich AA, Honscheid P, Sinicrope FA, Tindall DJ, Muders MH, Datta K. Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Res 2013; 73:160-71; PMID:23149913; http://dx.doi.org/10.1158/0008-5472.CAN-11-3635
   PubMed Web of Science ®Google Scholar
• Tang SC, Lagas JS, Lankheet NA, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 2012; 130:223-33; PMID:21351087; http://dx.doi.org/10.1002/ijc.26000
   PubMed Web of Science ®Google Scholar
• Yamagishi T, Sahni S, Sharp DM, Arvind A, Jansson PJ, Richardson DR. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013; 288:31761-71; PMID:24062304; http://dx.doi.org/10.1074/jbc.M113.514091
   PubMedGoogle Scholar
• Shukla S, Robey RW, Bates SE, Ambudkar SV. Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metab Dispos 2009; 37:359-65; PMID:18971320; http://dx.doi.org/10.1124/dmd.108.024612
   PubMed Web of Science ®Google Scholar
• Puissant A, Dufies M, Raynaud S, Cassuto JP, Auberger P. Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells. Leukemia 2010; 24:1099-101; PMID:20376083; http://dx.doi.org/10.1038/leu.2010.55
   PubMed Web of Science ®Google Scholar
• Lamark T, Johansen T. Autophagy: links with the proteasome. Curr Opin Cell Biol 2010; 22:192-8.; PMID:19962293; http://dx.doi.org/10.1016/j.ceb.2009.11.002
   PubMed Web of Science ®Google Scholar
• Einsele H. Bortezomib. Recent Results Cancer Res 2014; 201:325-45; PMID:24756802; http://dx.doi.org/10.1007/978-3-642-54490-3_20
   PubMedGoogle Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603; PMID:18650835; http://dx.doi.org/10.1038/nrc2442
   PubMed Web of Science ®Google Scholar
• Grau S, Thorsteinsdottir J, von Baumgarten L, Winkler F, Tonn JC, Schichor C. Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol 2011; 104:103-12; PMID:21308397; http://dx.doi.org/10.1007/s11060-010-0480-6
   PubMed Web of Science ®Google Scholar
• Giuliano S, Pages G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 2013; 95:1110-9; PMID:23507428; http://dx.doi.org/10.1016/j.biochi.2013.03.002
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8:210-21; PMID:21364524; http://dx.doi.org/10.1038/nrclinonc.2011.21
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Wei Y, Naylor RM, Williamson CW, Bhagwandin V, Tabruyn SP, You WK, Chapman HA, Christensen JG, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2:270-87; PMID:22585997; http://dx.doi.org/10.1158/2159-8290.CD-11-0240
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15:232-9; PMID:19249681; http://dx.doi.org/10.1016/j.ccr.2009.01.021
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15:220-31; PMID:19249680; http://dx.doi.org/10.1016/j.ccr.2009.01.027
   PubMed Web of Science ®Google Scholar
• Cao Y, Hoeppner LH, Bach S, E G, Guo Y, Wang E, Wu J, Cowley MJ, Chang DK, Waddell N, et al. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin. Cancer Res 2013; 73:4579-90; PMID:23689123; http://dx.doi.org/10.1158/0008-5472.CAN-13-0529
   PubMed Web of Science ®Google Scholar
• Sennino B, Ishiguro-Oonuma T, Schriver BJ, Christensen JG, McDonald DM. Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice. Cancer Res 2013; 73:3692-703; PMID:23576559; http://dx.doi.org/10.1158/0008-5472.CAN-12-2160
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010; 17:219-24; PMID:20308892
   PubMed Web of Science ®Google Scholar
• Sivanand S, Pena-Llopis S, Zhao H, Kucejova B, Spence P, Pavia-Jimenez A, Yamasaki T, McBride DJ, Gillen J, Wolff NC, et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci Transl Med 2012; 4:137ra75; PMID:22674553; http://dx.doi.org/10.1126/scitranslmed.3003643
   PubMed Web of Science ®Google Scholar
• Karam JA, Zhang XY, Tamboli P, Margulis V, Wang H, Abel EJ, Culp SH, Wood CG. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur Urol 2011; 59:619-28; PMID:21167632; http://dx.doi.org/10.1016/j.eururo.2010.11.043
   PubMed Web of Science ®Google Scholar
• Gerlach MM, Merz F, Wichmann G, Kubick C, Wittekind C, Lordick F, Dietz A, Bechmann I. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. Br J Cancer 2014; 110:479-88; PMID:24263061; http://dx.doi.org/10.1038/bjc.2013.700
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366:883-92; PMID:22397650; http://dx.doi.org/10.1056/NEJMoa1113205
   PubMed Web of Science ®Google Scholar
• Duvvuri M, Gong Y, Chatterji D, Krise JP. Weak base permeability characteristics influence the intracellular sequestration site in the multidrug-resistant human leukemic cell line HL-60. J Biol Chem 2004; 279:32367-72; PMID:15181006; http://dx.doi.org/10.1074/jbc.M400735200
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722-31; PMID:23964934; http://dx.doi.org/10.1056/NEJMoa1303989
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol 2014; 32:1412-8; PMID:24687826; http://dx.doi.org/10.1200/JCO.2013.50.8267
   PubMed Web of Science ®Google Scholar
• Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y. A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro 2011; 25:715-23; PMID:21184822; http://dx.doi.org/10.1016/j.tiv.2010.12.010
   PubMed Web of Science ®Google Scholar
• Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 2008; 8:175; PMID:18565219; http://dx.doi.org/10.1186/1471-2407-8-175
   PubMed Web of Science ®Google Scholar
• Ye J, Kumanova M, Hart LS, Sloane K, Zhang H, De Panis DN, Bobrovnikova-Marjon E, Diehl JA, Ron D, Koumenis C. The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 2010; 29:2082-96; PMID:20473272; http://dx.doi.org/10.1038/emboj.2010.81
   PubMed Web of Science ®Google Scholar
• Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26:4749-60; PMID:17297441; http://dx.doi.org/10.1038/sj.onc.1210289
   PubMed Web of Science ®Google Scholar
• Hamdan AM, Koyanagi S, Wada E, Kusunose N, Murakami Y, Matsunaga N, Ohdo S. Intestinal expression of mouse Abcg2/breast cancer resistance protein (BCRP) gene is under control of circadian clock-activating transcription factor-4 pathway. J Biol Chem 2012; 287:17224-31; PMID:22396548; http://dx.doi.org/10.1074/jbc.M111.333377
   PubMed Web of Science ®Google Scholar
• Zhu H, Xia L, Zhang Y, Wang H, Xu W, Hu H, Wang J, Xin J, Gang Y, Sha S, et al. Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PLoS ONE 2012; 7:e31431; PMID:22363646; http://dx.doi.org/10.1371/journal.pone.0031431
   PubMed Web of Science ®Google Scholar
• Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014; 26:190-206; PMID:25117709; http://dx.doi.org/10.1016/j.ccr.2014.06.025
   PubMed Web of Science ®Google Scholar
• Duvvuri M, Konkar S, Hong KH, Blagg BS, Krise JP. A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem Biol 2006; 1:309-15; PMID:17163760; http://dx.doi.org/10.1021/cb6001202
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004; 96:1702-13; PMID:15547183; http://dx.doi.org/10.1093/jnci/djh305
   PubMed Web of Science ®Google Scholar
• Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 1993; 265:C1015-29; PMID:8238296
   PubMed Web of Science ®Google Scholar
• Falasca M, Linton KJ. Investigational ABC transporter inhibitors. Expert Opin Investig Drugs 2012; 21:657-66; PMID:22493979; http://dx.doi.org/10.1517/13543784.2012.679339
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102:15545-50; PMID:16199517; http://dx.doi.org/10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003; 34:267-73; PMID:12808457; http://dx.doi.org/10.1038/ng1180
   PubMed Web of Science ®Google Scholar
• Pamer E, Cresswell P. Mechanisms of MHC class I–restricted antigen processing. Annu Rev Immunol 1998; 16:323-58; PMID:9597133; http://dx.doi.org/10.1146/annurev.immunol.16.1.323
   PubMed Web of Science ®Google Scholar
• Zaiss DM, Standera S, Kloetzel PM, Sijts AJ. PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A 2002; 99:14344-9; PMID:12374861; http://dx.doi.org/10.1073/pnas.212257299
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6:pl1; PMID:23550210; http://dx.doi.org/10.1126/scisignal.2004088
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2:401-4; PMID:22588877; http://dx.doi.org/10.1158/2159-8290.CD-12-0095
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos CR, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46:225-33; PMID:24487277; http://dx.doi.org/10.1038/ng.2891
   PubMed Web of Science ®Google Scholar
• Bilton R, Mazure N, Trottier E, Hattab M, Dery MA, Richard DE, Pouyssegur J, Brahimi-Horn MC. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem 2005; 280:31132-40; PMID:15994306; http://dx.doi.org/10.1074/jbc.M504482200
   PubMed Web of Science ®Google Scholar
• Grepin R, Guyot M, Giuliano S, Boncompagni M, Ambrosetti D, Chamorey E, Scoazec JY, Negrier S, Simonnet H, Pages G. The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res 2014; 74:873-83; PMID:24335961; http://dx.doi.org/10.1158/0008-5472.CAN-13-1267
   PubMed Web of Science ®Google Scholar